We provide new insights into the molecular mechanisms underlying tau pathology in Alzheimer’s disease and highlight FKBP8 receptor as a potential target for mitigating mitochondrial dysfunction in neurodegenerative diseases. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.